Active antifungal packaging is a technological solution for reducing the postharvest losses of fruits and vegetables associated with phytopathogens. Anthracnose (Colletotrichum gloeosporioides) is the principal fungus that causes post-harvest avocado fruit decay. In this study, antifungal sachets filled with oregano oil-starch capsules were prepared, and their active effects were demonstrated on Hass avocado fruits. Oregano oil (31 % of carvacrol) was encapsulated with corn starch by spray drying. Tyvek sachets (4 × 4 cm) filled with 80 (T1) and 160 mg (T2) of oregano oil-starch capsules (99.35 ± 1.86 mg g − 1) were fabricated. The antifungal effects of the sachets were tested in vitro and in vivo using a humidity chamber (90–95 % relative humidity (RH)) on fruits inoculated with anthracnose. The results showed that T1 and T2 inhibited 75.21 ± 2.81 and 100 % in vitro growth of anthracnose at 25 °C for 12 days. Furthermore, Hass avocado fruits stored in a humidity chamber at 25 °C for 6 days showed that only T2 significantly (p < 0.05) reduced the area of lesion produced by artificial inoculation of Hass avocado fruits with anthracnose. On average, the lesion area in the Hass avocado fruits treated with T2 was 13.94 % smaller than that in the control fruit.
MULTIFILE
Already for some decades lateral flow assays (LFAs) are ‘common use’ devices in our daily life. Also, for forensic use LFAs are developed, such as for the analysis of illicit drugs and DNA, but also for the detection of explosives and body fluid identification. Despite their advantages, including ease-of-use, LFAs are not yet frequently applied at a crime scene. This review describes (academic) developments of LFAs for forensic applications, focusing on biological and chemical applications, whereby the main advantages and disadvantages of LFAs for the different forensic applications are summarized. Additionally, a critical review is provided, discussing why LFAs are not frequently applied within the forensic field and highlighting the steps that are needed to bring LFAs to the forensic market.
Study goal: This study was carried out to answer the following research question: which motivation do healthy volunteers have to participate in phase I clinical trials? - Methods: A literature search was done through Google Scholar and Academic Search Premier, followed by three interviews with volunteers who had recently concluded their participation in a (non-commercial) phase I trial. - Results: Our literature search revealed mainly commercial motives for volunteers to participate in phase I clinical trials. The interviews (with volunteers in a non-commercial trial) showed that other factors may also play a decisive role, such as: (1) wish to support the investigator (2) wish to contribute to science, (3) access to more/better health care (4) sociability: possibility to relax and to communicate with other participants (5) general curiosity. Precondition is that risks and burden are deemed acceptable. - Conclusions: financial remuneration appears to be the predominant motive to participate voluntarily in a clinical trial. Other reasons were also mentioned however, such as general curiosity, the drive to contribute to science and the willingness to help the investigator. In addition, social reasons were given such as possibility to relax and to meet other people. Potential subjects state that they adequately assess the (safety) risks of participating in a trial as part of their decision process.
